Biologic drugs in the treatment of juvenile dermatomyositis: a literature review.

[1]  L. Rider,et al.  Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy , 2023, Arthritis & rheumatology.

[2]  V. Pascual,et al.  Association of Juvenile Dermatomyositis Disease Activity With the Expansion of Blood Memory B and T Cell Subsets Lacking Follicular Markers , 2023, Arthritis & rheumatology.

[3]  Haiguo Yu,et al.  Use of Adalimumab in a Child with Juvenile Dermatomyositis and Calcinosis , 2022, Indian Journal of Pediatrics.

[4]  H. Rockette,et al.  Randomized Trial of Tocilizumab in the Treatment of Refractory Adult Polymyositis and Dermatomyositis , 2022, ACR open rheumatology.

[5]  Xi-sheng Xu,et al.  Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis , 2022, Frontiers in Pediatrics.

[6]  M. Goldust,et al.  Adult and juvenile dermatomyositis treatment , 2022, Journal of cosmetic dermatology.

[7]  B. Feldman,et al.  The clinical features of juvenile dermatomyositis: A single-centre inception cohort. , 2022, Seminars in arthritis and rheumatism.

[8]  E. Ochfeld,et al.  Coding joint: kappa-deleting recombination excision circle ratio and B cell activating factor level: predicting juvenile dermatomyositis rituximab response, a proof-of-concept study , 2022, BMC Rheumatology.

[9]  D. Kleiner,et al.  Nodular Regenerative Hyperplasia of the liver in Juvenile Dermatomyositis , 2022, Pediatric Rheumatology.

[10]  A. Patwardhan,et al.  Is Anti-NXP2 Autoantibody a Risk Factor for Calcinosis and Poor Outcome in Juvenile Dermatomyositis Patients? Case Series , 2022, Frontiers in Pediatrics.

[11]  T. Price,et al.  Progressive, refractory macrophage activation syndrome as the initial presentation of anti-MDA5 antibody positive juvenile dermatomyositis: a case report and literature review , 2022, Pediatric Rheumatology.

[12]  J. Callen,et al.  Association of Treatment With Secukinumab With Exacerbation of Dermatomyositis in a Patient With Psoriasis. , 2022, JAMA dermatology.

[13]  S. Ito,et al.  Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review , 2022, Pediatric Rheumatology.

[14]  Connie L Yang,et al.  Juvenile Dermatomyositis and Acute Respiratory Failure in a Teen. , 2021, Chest.

[15]  Emily Schildt,et al.  Anasarca as the presenting symptom of juvenile dermatomyositis: a case series , 2021, Pediatric Rheumatology.

[16]  S. Kamphuis,et al.  Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response , 2021, Rheumatology.

[17]  D. Wahezi,et al.  Myositis autoantibodies in a racially diverse population of children with idiopathic inflammatory myopathies , 2021, Pediatric Rheumatology.

[18]  Hiba Khan,et al.  Juvenile dermatomyositis with gingival vasculopathy , 2021, Clinical Rheumatology.

[19]  C. Bodemer,et al.  JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. , 2021, Rheumatology.

[20]  C. Pilkington,et al.  Comparison of treatments and outcomes of children with juvenile dermatomyositis followed at two European tertiary care referral centers. , 2021, Rheumatology.

[21]  C. Papadopoulou,et al.  Treatment of Calcinosis in Juvenile Dermatomyositis , 2021, Current Rheumatology Reports.

[22]  Y. Lau,et al.  Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review , 2021, Pediatric Rheumatology.

[23]  L. Wedderburn,et al.  The Vasculopathy of Juvenile Dermatomyositis: Endothelial Injury, Hypercoagulability, and Increased Arterial Stiffness , 2021, Arthritis & rheumatology.

[24]  C. Günther,et al.  Interferon signature guiding therapeutic decision making: ruxolitinib as first-line therapy for severe juvenile dermatomyositis? , 2020, Rheumatology.

[25]  K. Minden,et al.  Myositis-specific autoantibodies and their associated phenotypes in juvenile dermatomyositis: data from a German cohort. , 2020, Clinical and experimental rheumatology.

[26]  Yuchuan Ding,et al.  Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis , 2020, Annals of the Rheumatic Diseases.

[27]  A. Remesal,et al.  Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report , 2020, Modern rheumatology case reports.

[28]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2020, BMJ.

[29]  I. Pinal-Fernandez,et al.  Risk factors associated with Pneumocystis jirovecii pneumonia in juvenile myositis in North America. , 2020, Rheumatology.

[30]  B. Sözeri,et al.  A striking treatment option for recalcitrant calcinosis in juvenile dermatomyositis: tofacitinib citrate. , 2020, Rheumatology.

[31]  Yuchuan Ding,et al.  Clinical characteristics and poor predictors of anti-NXP2 antibody-associated Chinese JDM children , 2020, Pediatric Rheumatology.

[32]  Vini Vijayan,et al.  Abatacept in the Treatment of Juvenile Dermatomyositis-Associated Calcifications in a 16-Year-Old Girl , 2020, Case reports in rheumatology.

[33]  T. Southwood,et al.  Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients , 2020, Arthritis Research & Therapy.

[34]  Laura Cannon,et al.  Juvenile Dermatomyositis and Development of Malignancy: 2 Case Reports and a Literature Review , 2020, The Journal of Rheumatology.

[35]  C. Bodemer,et al.  Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-α signalling. , 2019, Rheumatology.

[36]  S. Rosenzweig,et al.  Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. , 2019, Brain : a journal of neurology.

[37]  U. Müller-Ladner,et al.  Use of vasoactive/vasodilating drugs for systemic sclerosis (SSc)-related digital ulcers (DUs) in expert tertiary centres: results from the analysis of the observational real-life DeSScipher study , 2019, Clinical Rheumatology.

[38]  C. Papadopoulou,et al.  Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis , 2019, Brain : a journal of neurology.

[39]  V. Dharnidharka,et al.  Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis , 2018, Pediatric Rheumatology.

[40]  C. Bodemer,et al.  A child with severe juvenile dermatomyositis treated with ruxolitinib. , 2018, Brain : a journal of neurology.

[41]  A. Hersh,et al.  Retinal Manifestations of Juvenile Dermatomyositis: Case Report of Bilateral Diffuse Chorioretinopathy with Paracentral Acute Middle Maculopathy and Review of the Literature , 2018, Ocular immunology and inflammation.

[42]  C. Bodemer,et al.  Presentations and outcomes of juvenile dermatomyositis patients admitted to intensive care units. , 2017, Rheumatology.

[43]  A. Huber,et al.  Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA) , 2017, Pediatric Rheumatology.

[44]  S. Al‐Mayouf,et al.  Phenotypic characteristics and outcome of juvenile dermatomyositis in Arab children , 2017, Rheumatology International.

[45]  H. Kim,et al.  Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America , 2017, Pediatric Rheumatology.

[46]  A. Rawat,et al.  Autoantibodies in children with juvenile dermatomyositis: A single centre experience from North-West India , 2017, Rheumatology International.

[47]  C. Oddis,et al.  Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab , 2017, Rheumatology.

[48]  O. Kasapcopur,et al.  Juvenile dermatomyositis: a tertiary center experience , 2017, Clinical Rheumatology.

[49]  J. Wilmshurst,et al.  Characteristics and outcome of children with juvenile dermatomyositis in Cape Town: a cross-sectional study , 2016, Pediatric Rheumatology.

[50]  L. Fotis,et al.  Four Cases of Anti-PM/Scl Antibody-positive Juvenile Overlap Syndrome with Features of Myositis and Systemic Sclerosis , 2016, The Journal of Rheumatology.

[51]  N. Wulffraat,et al.  Consensus-based recommendations for the management of juvenile dermatomyositis , 2016, Annals of the rheumatic diseases.

[52]  B. De Paepe,et al.  Scanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory Myopathies , 2015, International journal of molecular sciences.

[53]  B. Weiss,et al.  Infliximab-Related Infusion Reactions: Systematic Review , 2015, Journal of Crohn's & colitis.

[54]  Yao-Hsu Yang,et al.  Juvenile dermatomyositis: a 20-year retrospective analysis of treatment and clinical outcomes. , 2015, Pediatrics and neonatology.

[55]  I. Sjaastad,et al.  Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool. , 2014, Rheumatology.

[56]  Chiang-Ching Huang,et al.  Pilot Study of Etanercept in Patients With Refractory Juvenile Dermatomyositis , 2014, Arthritis care & research.

[57]  V. Lilleby,et al.  Severe macrophage activation syndrome and central nervous system involvement in juvenile dermatomyositis , 2014, Scandinavian journal of rheumatology.

[58]  C. Massone,et al.  New Onset of Dermatomyositis/Polymyositis during Anti-TNF-α Therapies: A Systematic Literature Review , 2014, TheScientificWorldJournal.

[59]  M. Tikly,et al.  Juvenile dermatomyositis in South African children is characterised by frequent dystropic calcification: a cross sectional study , 2014, Pediatric Rheumatology.

[60]  R. Petty,et al.  Severe Vocal Cord Dysfunction: An Unusual Complication of Juvenile Dermatomyositis , 2013, The Journal of Rheumatology.

[61]  C. Hawkins,et al.  Anti-signal Recognition Particle-positive Juvenile Polymyositis Successfully Treated with Rituximab , 2012, The Journal of Rheumatology.

[62]  R. Silverman,et al.  Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. , 2012, The Journal of pediatrics.

[63]  L. Mouthon,et al.  Therapy of polymyositis and dermatomyositis. , 2011, Autoimmunity reviews.

[64]  C. Bodemer,et al.  Safety and Efficacy of Rituximab in Severe Juvenile Dermatomyositis: Results from 9 Patients from the French Autoimmunity and Rituximab Registry , 2011, The Journal of Rheumatology.

[65]  J. Jarvis,et al.  Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis. , 2011, Archives of dermatology.

[66]  V. Werth,et al.  Tumor necrosis factor inhibitor-associated dermatomyositis. , 2010, Archives of dermatology.

[67]  A. Martini,et al.  Long‐term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients , 2010, Arthritis care & research.

[68]  N. Wulffraat,et al.  Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis , 2010, Scandinavian journal of rheumatology.

[69]  P. Woo,et al.  Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. , 2008, Rheumatology.

[70]  M. Cooper,et al.  Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. , 2007, Arthritis and rheumatism.

[71]  L. Rider.  The heterogeneity of juvenile myositis. , 2007, Autoimmunity reviews.

[72]  R. Av,et al.  Clinical outcomes in juvenile dermatomyositis. , 2002 .

[73]  E. Çakır,et al.  A fatal interstitial lung disease in an anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody negative patient with juvenile dermatomyositis. , 2021, The Turkish journal of pediatrics.

[74]  M. D. Ruiz Montesino,et al.  Treatment With Rituximab in Juvenile Dermatomyositis: Effect on Calcinosis. , 2018, Reumatologia clinica.

[75]  L. Wedderburn,et al.  Juvenile dermatomyositis: Latest advances. , 2017, Best practice & research. Clinical rheumatology.

[76]  H. Rockette,et al.  Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. , 2013, Arthritis and rheumatism.

[77]  D. Foell,et al.  B cell depletion for autoimmune diseases in paediatric patients , 2010, Clinical Rheumatology.

[78]  H. Prince,et al.  Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases. , 2007, Journal of the American Academy of Dermatology.